Coherus Oncology
CA - Redwood City
BiotechnologyFocus: Biologics, Biosimilars
Coherus Oncology is a life sciences company focused on Biologics, Biosimilars.
Oncology
Open Jobs
8
Pipeline & Clinical Trials
Pegfilgrastim-Cbqv
Febrile NeutropeniaClinical Trials (1)
NCT04662892An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
N/ACHS-1701
HealthyClinical Trials (1)
NCT02650973Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta
Phase 1CHS-1701
BioequivalenceClinical Trials (1)
NCT02385851Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)
Phase 1Phase 1
Clinical Trials (1)
NCT06389526A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Phase 1SRF617
Advanced Solid TumorClinical Trials (1)
NCT04336098Study of SRF617 in Patients With Advanced Solid Tumors
Phase 1CHS-006
Advanced Solid TumorClinical Trials (1)
NCT05757492Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Phase 1CHS-114
Advanced Solid TumorClinical Trials (1)
NCT05635643Study of CHS-114 in Participants With Advanced Solid Tumors
Phase 1CHS-114
Metastatic Solid TumorClinical Trials (1)
NCT06657144A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Phase 1CHS-388
Advanced Solid TumorClinical Trials (1)
NCT04374877Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Phase 1CHS-1701
Immunity, HumoralClinical Trials (1)
NCT02418104Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®
Phase 1STC-15 in combination with toripalimab
Metastatic Non-small Cell Lung CancerClinical Trials (1)
NCT06975293STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
Phase 1/2Dupilumab
Metastatic Colorectal CancerClinical Trials (1)
NCT07277322Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT07281716Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Phase 1/2Biopsy Procedure
Localized Colon CarcinomaClinical Trials (1)
NCT07140679Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Phase 2Toripalimab + Chemotherapy
Head and Neck CancerClinical Trials (1)
NCT07209189Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Phase 2Casdozokitug
Hepatocellular CarcinomaClinical Trials (1)
NCT06679985A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Phase 2Toripalimab-tpzi
Squamous Cell CarcinomaClinical Trials (1)
NCT07214987PDT For Induction Therapy For Head And Neck Cancer
Phase 2Toripalimab
Sinonasal CancerClinical Trials (1)
NCT06940180Toripalimab With Chemotherapy for Sinus Cancer
Phase 2NY-ESO-1 Peptide vaccine
Ovarian Cancer Stage IVClinical Trials (1)
NCT05479045A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Phase 2Clinical Trials (1)
NCT07423078Window of Opportunity in Preserving Laryngeal Function Trial
Phase 2Phase 2
Clinical Trials (1)
NCT05177770Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 2SRF388
Hepatocellular CarcinomaClinical Trials (1)
NCT05359861Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Phase 2Etanercept
Plaque PsoriasisClinical Trials (1)
NCT02134210Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Phase 3CHS-0214
Rheumatoid ArthritisClinical Trials (1)
NCT02486939A Long Term Safety Extension Study (CHS-0214-05)
Phase 3Etanercept
Rheumatoid ArthritisClinical Trials (1)
NCT02115750Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
Phase 3CHS-1420
Plaque PsoriasisClinical Trials (1)
NCT02489227Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
Phase 3Toripalimab
Nasopharyngeal Cancer RecurrentClinical Trials (1)
NCT06457503A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Phase 4Open Jobs (8)
Associate Director, Drug Product Manufacturing
Redwood City, CA
Supply Chain1w ago
$170K - $200K/yr
Clinical Research Associate
Redwood City, CA
Clinical 2w ago
$90K - $110K/yr
Oncology Account Manager
Orlando, FL
Commercial1mo ago
$150K - $200K/yr
Director, Thought Leader Strategy, I/O Commercial Franchise
Remote
Commercial1mo ago
$190K - $240K/yr
QC Senior Specialist, Quality Laboratory
Camarillo, CA
Quality Assurance1mo ago
$115K - $145K/yr
Sr. Manager, Investor Relations
Redwood City, CA
Investor Relations & Corporate Communications1mo ago
$140K - $175K/yr
Director, CMC and Life Cycle Management (LCM) Lead
Redwood City, CA
Supply Chain2mo ago
$190K - $240K/yr
Oncology Account Manager
Houston, TX
Commercial3mo ago
$150K - $200K/yr
Interview Prep Quick Facts
Portfolio: 27 clinical trials
Top TAs: Oncology, Immunology
Open Roles: 8 active jobs
Hiring Trend
Slowing Down
8
Open Roles
+0
Added
-4
Filled/Removed
Based on last 4 crawl cycles